导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.17% | 3553/4773 |
| 近一周 | -1.60% | 2960/5467 |
| 近一月 | -3.14% | 1145/5421 |
| 近一季 | 0.81% | 882/5238 |
| 近半年 | -6.05% | 3248/4931 |
| 近一年 | -11.99% | 3462/4400 |
| 近两年 | 37.30% | 2002/2954 |
| 近三年 | 34.94% | 899/2253 |
| 成立以来 | 10.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.03% 3751/4961 |
-8.62% 3905/5312 |
- - |
- - |
| 2025 | 26.70% 1609/4813 |
14.93% 193/3635 |
3.95% 899/4076 |
11.85% 3123/4524 |
-5.19% 3521/4813 |
| 2024 | 23.16% 347/3463 |
-1.49% 1233/2808 |
9.86% 47/3014 |
14.92% 1876/3129 |
-0.97% 1557/3463 |
| 2023 | -10.51% 1311/2656 |
0.32% 1743/2280 |
-0.03% 355/2385 |
-8.23% 1682/2515 |
-2.76% 524/2655 |
| 2022 | -4.73% 104/2207 |
-6.75% 227/1919 |
6.00% 792/2016 |
-14.61% 1125/2113 |
12.88% 117/2208 |
| 2021 | -12.54% 1129/1822 |
4.38% 150/1255 |
0.05% 1115/1330 |
-11.35% 1263/1466 |
-5.53% 1517/1822 |
| 2020 | -5.04% 966/1250 |
-13.33% 163/280 |
5.23% 223/295 |
-7.25% 1131/1164 |
12.25% 487/1184 |
| 2019 | 12.38% 717/1092 |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏沪港通恒生ETF联接C VS. 长安沪深300非周期A(740101) |